A Proof of Concept Study of Time Limited Exercise Plus Olanzapine-samidorphan for the Prevention of Early Weight Gain
New York State Psychiatric Institute
Summary
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
Description
The principal hypothesis is that Olz/Sam combined with aerobic exercise will lead to less weight gain than Olz/Sam alone (historical data) when measured at 4 weeks. People with schizophrenia, schizoaffective and bipolar disorder I,II and NOS are eligible. After informed consent, patients will undergo a full medical/psychiatric screening and be assessed for a reason to switch antipsychotic medication. Eligible subjects will receive 8 weeks of open label Olz/Sam. Over the first 4 weeks of treatment, all subjects will complete 4 weeks of aerobic exercise for 2 to 4 days a week. Olanzapine will b…
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age between 18-65, inclusive at Visit 1. 2. DSM-V diagnosis of schizophrenia or schizoaffective or Bipolar I/II/NOS disorder at Visit 1. 3. Body Mass Index (BMI) of 18.0-40.0 kg/m2, inclusive, at Visits 1 and 2. 4. Willing to provide informed consent at Visit 1. 5. Medically and psychiatrically stable for study participation at Visit 1. 6. Responsive to an antipsychotic treatment (other than clozapine) in the past 5 years prior to Visit 1. 7. Can benefit from participation in this study and has a reason to participate, such as inadequate efficacy on current treatment, s…
Interventions
- DrugOlanzapine-samidorphan + exercise
8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise
Location
- New York State Psychiatric InstituteNew York, New York